Predicting late radiation-associated neurocognitive and endocrine toxicity in patients with brain tumors
Kyle Tuohy, Aarav Badani, Ava Franklin, Brad Zacharia, Dawit Aregawi, Alireza Mansouri, Paul Brown, Michael Glantz · 2026
Read Predicting late radiation-associated neurocognitive and endocrine toxicity in patients with brain tumors by Kyle Tuohy, Aarav Badani, Ava Franklin, Brad Zacharia, Dawit Aregawi, Alireza Mansouri, Paul Brown, Michael Glantz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219158.txt.
Description
Kyle Tuohy and colleagues search for pre-treatment clues to who will suffer brain and hormone damage after radiation in a 2026 cohort study. Radiation remains central to treating primary and metastatic brain tumors, but thinking problems and hormone failure can surface afterward, and doctors cannot forecast them. Better prediction would let clinicians warn patients and design preventive studies.
Eighty patients treated at one institution with radiation as part of tumor therapy were assessed across five toxicity measures, with change on a mental status exam as the main outcome. Two findings stood out in adjusted models as the strongest predictors of decline: elevated homocysteine, an amino acid linked to vascular injury, and carrying the ApoE4 variant, tied to Alzheimer's risk. Homocysteine tracked with white matter change on MRI, and ApoE4 with new hormone deficiencies. The team built a nomogram estimating patient risk across all five outcomes and calls for validation.
Catalog record
| CREATOR | Kyle Tuohy, Aarav Badani, Ava Franklin, Brad Zacharia, Dawit Aregawi, Alireza Mansouri, Paul Brown, Michael Glantz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |